Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What’s driving the optimism?

Cipla’s stock surged following Citi’s ‘Buy’ rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US approvals like gFlovent and gVentolin, alongside a rebound in its US business. Domestically, Cipla’s performance remains strong, supported by its respiratory portfolio. Citi sees earnings bottoming out and highlights attractive valuations for the Indian market.